Arcus Biosciences, Inc. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

Arcus Biosciences, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $117.00 million for the year ending 2023.

  • Arcus Biosciences, Inc. showed an increase of +4.5% in Revenue From Contract With Customer Excluding Assessed Tax from 2022 to 2023.
  • This data is from Arcus Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 21, 2024.
  • XBRL data for this metric is available from 2018 to 2023 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2018 to 2023), Arcus Biosciences, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 1,300.7%.
  • Historical annual values: Fiscal year 2023: $117.00 million | Fiscal year 2022: $112.00 million | Fiscal year 2021: $383.00 million | Fiscal year 2020: $78.00 million | Fiscal year 2019: $15.00 million | Fiscal year 2018: $8.35 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: